These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28249243)

  • 1. A recombinant IgG-like bispecific antibody acting as interleukin-1β and interleukin-17A inhibitor exhibits a promising efficacy for rheumatoid arthritis.
    Wang Y; Wu Q; Liu Z; Guo X; Zhou L; Wang Y; Song L; Wang N; Zheng Q; Wang W; Ren G; Li D
    Biomed Pharmacother; 2017 May; 89():426-437. PubMed ID: 28249243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bispecific antibody aimed at the vicious circle of IL-1β and IL-17A, is beneficial for the collagen-induced rheumatoid arthritis of mice through NF-κB signaling pathway.
    Wu Q; Wang Y; Wang Q; Yu D; Wang Y; Song L; Liu Z; Ye X; Xu P; Cao H; Li D; Ren G
    Immunol Lett; 2016 Nov; 179():68-79. PubMed ID: 27616043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immuno-blocking agent targeting IL-1β and IL-17A reduces the lesion of DSS-induced ulcerative colitis in mice.
    Yin Q; Pi X; Jiang Y; Ren G; Liu Z; Liu H; Wang M; Sun W; Li S; Gao Z; Li D; Yin J
    Inflammation; 2021 Oct; 44(5):1724-1736. PubMed ID: 33877484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model.
    Li Q; Ren G; Xu L; Wang Q; Qi J; Wang W; Zhou B; Han X; Sun C; Wu Q; Yu Y; Peng Z; Zheng S; Li D
    Int Immunopharmacol; 2014 Jul; 21(1):119-27. PubMed ID: 24800661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel bispecific antibody alleviates bleomycin-induced systemic sclerosis injury.
    Yin Q; Pi X; Ren G; Liu Z; Liu H; Wang M; Hu C; Zhao H; Li D; Yin J
    Int Immunopharmacol; 2020 Aug; 85():106644. PubMed ID: 32474387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis.
    Qi J; Kan F; Ye X; Guo M; Zhang Y; Ren G; Li D
    Int Immunopharmacol; 2012 Dec; 14(4):770-8. PubMed ID: 23092552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.
    Zhang Y; Ren G; Guo M; Ye X; Zhao J; Xu L; Qi J; Kan F; Liu M; Li D
    Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
    Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G
    Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic efficacy of three bispecific antibodies on rheumatoid arthritis mice models].
    Li QC; Han XH; Zhou B; Wang WF; Ren GP; Sun CY; Wu Q; Yu YH; Xu LM; Wang QY; Qi JY; Wei YQ; Cao HW; Han JY; Li DS
    Yao Xue Xue Bao; 2014 Mar; 49(3):322-8. PubMed ID: 24961102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis.
    Qi J; Ye X; Ren G; Kan F; Zhang Y; Guo M; Zhang Z; Li D
    Mol Immunol; 2014 Feb; 57(2):59-65. PubMed ID: 24091292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fusion protein attenuates collagen-induced arthritis by targeting interleukin 17A and tumor necrosis factor α.
    Liu Z; Song L; Wang Y; Xu P; Guo X; Yang J; Liu H; Wang Y; Wu C; Zhang T; Yu D; Opoku YK; Khoso MH; Ren G; Li D
    Int J Pharm; 2018 Aug; 547(1-2):72-82. PubMed ID: 29803792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of IL-17 alleviated inflammation in rat arthritis and MMP-13 expression.
    Shui XL; Lin W; Mao CW; Feng YZ; Kong JZ; Chen SM
    Eur Rev Med Pharmacol Sci; 2017 May; 21(10):2329-2337. PubMed ID: 28617559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis.
    Kang SE; Park JK; Yoo HJ; Kang HS; Park YW; Park BC; Park JE; Lee EY; Lee EB; Song YW
    Transl Res; 2021 Jun; 232():75-87. PubMed ID: 33453429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A.
    Zheng S; Shen F; Jones B; Fink D; Geist B; Nnane I; Zhou Z; Hall J; Malaviya R; Ort T; Wang W
    MAbs; 2020; 12(1):1770018. PubMed ID: 32544369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of an anti-IL-1β scfv and TNFRI fusion protein and its therapeutic effect on RA mice model.
    Kan F; Ren G; Guo M; Qi J; Zhang Y; Han Y; Zhang Y; Li D
    Curr Pharm Biotechnol; 2014; 14(12):1048-61. PubMed ID: 24433504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis.
    Eljaafari A; Tartelin ML; Aissaoui H; Chevrel G; Osta B; Lavocat F; Miossec P
    Arthritis Rheum; 2012 Jul; 64(7):2147-57. PubMed ID: 22275154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A.
    Xu T; Ying T; Wang L; Zhang XD; Wang Y; Kang L; Huang T; Cheng L; Wang L; Zhao Q
    Oncotarget; 2017 Oct; 8(47):81860-81872. PubMed ID: 29137228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis.
    Bai F; Tian H; Niu Z; Liu M; Ren G; Yu Y; Sun T; Li S; Li D
    Int J Mol Med; 2014 Mar; 33(3):711-21. PubMed ID: 24378614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.
    Lyman M; Lieuw V; Richardson R; Timmer A; Stewart C; Granger S; Woods R; Silacci M; Grabulovski D; Newman R
    J Biol Chem; 2018 Jun; 293(24):9326-9334. PubMed ID: 29678878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.